← back to search

Hideaki Kato

Shizuoka University · JP
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Hepatitis B Virus Studies, and Hepatitis C virus research.
h-index
42
citations
8,737
works
351
NIH funding
primary concept
Medicine
email

Recent publications

In vitro activity of cefiderocol against carbapenem-resistant Gram-negative pathogens in Japan
Journal of Infection and Chemotherapy 2026cited by 1position: contributordoi
Identification of Putative Serum Autoantibodies Associated with Post-Acute Sequelae of COVID-19 via Comprehensive Protein Array Analysis.
2025cited by 3position: contributordoi
Effects of Long COVID in Patients with Severe Coronavirus Disease 2019 on Long-Term Functional Impairments: A Post Hoc Analysis Focusing on Patients Admitted to the ICU in the COVID-19 Recovery Study II.
2025cited by 3position: contributordoi
SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID.
2025cited by 1position: contributordoi
The relationship between the phenotype of long COVID symptoms and one-year psychosocial outcomes: an exploratory clustering analysis.
2025cited by 1position: contributordoi
Molecular epidemiology and patient outcome of carbapenem-resistant <i>Enterobacterales, Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Japan: a multicenter study from MultiDrug-Resistant organisms clinical research network.
2025cited by 1position: contributordoi
Infectious Complications in Patients Receiving Superselective Intra-Arterial Chemoradiotherapy for Oral Squamous Cell Carcinoma.
2025cited by 0position: contributordoi
Enhanced Detection of SARS-CoV-2 Using Platinum-Decorated Poly(2-vinylpyridine) Nanoparticle-Based Lateral Flow Immunoassay.
2025cited by 0position: contributordoi
Humoral and Cell-Mediated Immunity Against SARS-CoV-2 in Healthcare Personnel Who Received Multiple mRNA Vaccines: A 4-Year Observational Study.
2025cited by 0position: contributordoi
Accuracy of an Optical Waveguide-Based Biosensor Antigen-Detection Test for Severe Acute Respiratory Syndrome Coronavirus-2 and Seasonal Influenza Viruses During the Cocirculating Season.
2025cited by 0position: contributordoi
Long-term functional prognosis with tocilizumab in severe COVID-19 infection: A multicenter prospective observational study on mechanically ventilated ICU patients in the COVID-19 recovery study II.
2025cited by 0position: contributordoi
Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset.
2025cited by 0position: contributordoi
COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)
Vaccine 2024cited by 9position: contributordoi
Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan
Open Forum Infectious Diseases 2023cited by 15position: middledoi
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Vaccine 2023cited by 12position: middledoi
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
2023cited by 12position: contributordoi
COVID-19 vaccine effectiveness against severe COVID-19 requiring oxygen therapy, invasive mechanical ventilation, and death in Japan: A multicenter case-control study (MOTIVATE study)
Vaccine 2023cited by 11position: middledoi
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Vaccine 2023cited by 9position: contributordoi
Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.
2023cited by 7position: contributordoi
Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing <i>Escherichia coli</i>.
2023cited by 6position: contributordoi
Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies
Eurosurveillance 2023cited by 5position: middledoi
Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects.
2023cited by 4position: contributordoi
Cryptococcal meningitis with atypical paradoxical inflammatory reactions after antifungal treatment in acquired immune deficiency syndrome: A case report.
2023cited by 2position: contributordoi
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study)
Clinical Infectious Diseases 2022cited by 76position: middledoi
Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan
Journal of Global Antimicrobial Resistance 2022cited by 32position: contributordoi
Characterization and Utilization of Disulfide-Bonded SARS-CoV-2 Receptor Binding Domain of Spike Protein Synthesized by Wheat Germ Cell-Free Production System.
2022cited by 11position: contributordoi
Severity predictors of COVID-19 in SARS-CoV-2 variant, delta and omicron period; single center study.
2022cited by 6position: contributordoi
Expansion of droplets during speaking and singing in Japanese.
2022cited by 3position: contributordoi
Prospective Clinical Evaluation of the Diagnostic Accuracy of a Highly Sensitive Rapid Antigen Test Using Silver Amplification Technology for Emerging SARS-CoV-2 Variants.
2022cited by 0position: contributordoi
Severity Predictors of COVID-19 in SARS-CoV-2 Variant, Delta and Omicron Period; Single Center Study
2022cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 32 papers (2019–2026)K. Nakamura · Springer Nature3 papers (2025–2025)Yasufumi Matsumura · Elsevier, Inc.3 papers (2023–2025)Takeshi Arashiro · Elsevier, Inc.3 papers (2023–2024)Fumihiro Ogawa · Kitasato University3 papers (2020–2022) · 3 papers (2025–2026)Yohei Doi · University of Pittsburgh3 papers (2025–2026)Naoya Itoh · Nagoya City University2 papers (2025–2026)Martin L. Hibberd · London School of Hygiene & Tropical Medicine2 papers (2023–2024)Koh Shinohara · Elsevier, Inc.2 papers (2023–2025)Chris Smith · London School of Hygiene & Tropical Medicine2 papers (2023–2024)Kei Miyakawa · National Institute of Infectious Diseases2 papers (2023–2025) · 2 papers (2024–2025)Ashley Stucky · National Institute of Infectious Diseases2 papers (2023–2024)Junji Hatakeyama · Springer Nature2 papers (2025–2025)Akira Kawauchi · Johns Hopkins University2 papers (2025–2025) · 2 papers (2025–2025)Miyuki Hori · Global Policy Institute2 papers (2025–2025)David van Duin · University of North Carolina at Chapel Hill2 papers (2025–2025)Takeya Tsutsumi · Tokyo Medical University Hospital2 papers (2024–2025)